DURECT Corporation (NASAQD:DRRX) has announced the company’s participation in the Piper Jaffray 21st Annual Piper Jaffray Healtch Care Conference on Tuesday, December 1. The conference is being held at The New York Palace Hotel in New York City. DURECT Chief Financial Officer Matt Hogan, and Chief Medical Officer Joe Stauffer will speak at the conference at 3:30 pm ET. The company’s presentation will be available on the company’s website, http://www.durect.com/, on the Investor Relations page.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
DURECT Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms. The Company’s pharmaceutical systems enable optimized therapy for a given disease or patient population by controlling the rate and duration of drug administration, as well as for certain applications, placement of the drug at the intended site of action. DURECT Corporation’s drug delivery technology platforms include SABER Delivery System, ORADUR Delivery System, TRANSDUR Delivery System, DURIN Biodegradable Implant, DUROS System and MICRODUR. The Company’s development efforts are focused on the application of its pharmaceutical systems technologies to products in a variety of chronic and episodic disease areas, including pain, central nervous system (CNS) disorders, cardiovascular disease and other chronic diseases.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
